BioSpace BioPharm Exec
Wednesday, January 28, 2009
Off On the Right Hand in 2009

This year's J.P. Morgan Healthcare conference in San Francisco took a sinister turn. When Genentech's Art Levinson took the stage, he pointed out that the DNA helix on the official meeting logo, splashed on every badge, had a left-handed spiral--something that doesn't occur in nature. Oops!

Kudos to Levinson on his powers of observation. But perhaps the meeting organizers were making a symbolic rather than a literal statement. It seems like biotech's corkscrew has been spinning endlessly into the ground over the past year, and the question at this year's meeting, the unofficial kickoff to the life science's Year of the Ox, is whether we're soon going to see change we can believe in.

Certainly at ground level the industry will see unavoidable change. Biotech companies will have to continue to do more with less, and that unfortunately means some companies will probably pursue more "Hail Mary" phase 2 programs that push compounds into pivotal trials before enough is really known about them. The upshot will be more risk pushed onto shareholders who probably don't appreciate the difference between a well-vetted phase 2 program and a quick "shot on goal." And that could in turn increase the perceived risk of drug development and further depress investment dollars, a vicious cycle in the making.

Not that this is unavoidable. Personally, I'd like to see venture capital investment more focused on developing platform technologies and less on leveraging the single-product opportunities that have been so popular over the last few years ...and that again leave shareholders with more risk that I think they typically appreciate. More...

--Karl Thiel

More By Karl Thiel

Elan has lately been making news for what it's not doing. First, it's not in talks to be acquired by Pfizer, according to CEO Kelly Martin. (Shortly after making this claim, however, the company brought on Citigroup to explore strategic options, including a sale or merger.) Second, Elan is not extending phase 3 trials of bapineuzumab, its Alzheimer's treatment. A Bloomberg News report indicated otherwise, which put more pressure on the company's already troubled stock and besieged management. Actually, a lot of clinical news this past month is more about what is going to happen soon rather than what is happening now. A number of key study results are expected over the next few weeks--Intermune's pulmonary fibrosis drug and Synta's melanoma drug, for instance--and an absolute slew of data is expected around mid-year. -KT
Elan Corporation PLC (ELN) Clarifies Duration of Bapineuzumab Phase 3 Trials

Genentech, Inc. (DNA) Updates Colon Cancer Trial Timeline

ReNeuron To Launch Pioneering Stem Cell Trial

Novartis Corporation (NVS)'s RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments

Orexigen Therapeutics, Inc. (OREX) Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints

More Bench To Clinic News
Comparability Challenges: Regulatory and Scientific Issues in the Assessment of Biopharmaceuticals DIA - Comparability Challenges
Regulatory and Scientific Issues in the Assessment of Biopharmaceuticals. Recognize the information needed to assure comparability of product made by current and proposed new manufacturing processes; and review the previous approaches and the FDA perspective of such evaluations.
Aptuit Aptuit is a pharmaceutical services company focused on streamlining and supporting the drug development process for biotech and pharma innovators. Aptuit has been engineering a better drug development process by amassing a staff of consummate professionals, breakthrough technologies, facilities and new ideas to offer its clients seamless and globally integrated services.
Nobody can accuse the Obama Administration of wasting time when it comes to making political appointments. His cabinet was filled in record time, and it has become reasonable to think that the role of FDA commissioner--often a political afterthought that in the case of former president George W. Bush remained vacant for over two years--will be quickly filled. Indeed, an appointment may already have been made by the time you read this, but as of this writing, media outlets are reporting a very short list and predicting an imminent decision. In Vivo Blog suggests it's down to two names: Baltimore Commissioner of Health Joshua Sharfstein and Duke University researcher Robert Califf. Sharfstein is already working on the team for the Health and Human Services transition, which In Vivo suggests might give him an edge. What's truly remarkable, however, is that we probably won't have to wait long to find out. -KT
FDA Commissioner Update: Califf's Name Emerges, But Is Sharfstein the Pick?

Pfizer Inc. (PFE) (JOBS) May Fire 2,400, One-Third of U.S. Sales Force

Alcon Laboratories, Inc. (ACL) Names Insider Kevin Buehler as New CEO

Accelrys Inc. (ACCL) Announces Resignation of Chief Executive Officer and Appointment of Interim Chief Executive Officer

ImmunoGen, Inc. (IMGN) Names New CEO

Despite Economic Woes, Plenty of Biotech Jobs

More Career Track News
Molecular Medicine Tri-Conference Molecular Medicine Tri-Conference provides the breadth and depth of information critical to your organization's success. The 2009 event includes ELEVEN parallel tracks that provide compelling and in-depth insight into the future of molecular medicine.
11th Annual BIO CEO & Investor Conference 11th Annual BIO CEO & Investor Conference
Discover companies that aren't on everybody's radar screen. See their leadership teams in action, learn first hand about the science on which their futures depend, and meet privately with company CEOs. No other investor conference features such high-level discussions between MDs, CSOs and industry analysts.
Belgium's Galapagos NV may be named for a place that moves at the slow pace of evolution, but the company has lately been advancing pretty briskly. A big deal with Merck on obesity/diabetes targets was closely followed by an expansion of an existing partnership with GlaxoSmithKline on anti-infectives. And the company recently scored a couple milestone payments under programs with Janssen and GlaxoSmithKline.

Meanwhile, on the less friendly side of the deal-making world, Exact Sciences is trying to fight back against a hostile bid from Sequenom. Given that the money-losing company only has six months of cash left, I'm not sure how wise it is to turn down a deal that represented a 68% premium to Exact's stock price at the time it was offered. But Exact's job is to maximize return to shareholders, and if they believe their patent portfolio or anything else can substantially sweeten the deal, more power to them. They have a good fit with Sequenom, so it's not clear to me there will be other offers in the wings. -KT
Galapagos NV (GLPG.BR) Partners with Merck & Co., Inc. (MRK), GLPG Shares Jump; Total Payments Could Exceed $233 Million

Sequenom Inc. (SQNM) Makes Hostile Bid for EXACT Sciences Corporation (EXAS)

Genentech, Inc. (DNA) Calms Talk of New Roche (RHHBY) Offer

Cephalon, Inc. (CEPH) Signs Option Agreement to Acquire Ception Therapeutics; Cephalon Will Pay Ception $100 Million Upfront

Elan Corporation PLC (ELN) CEO Says Not in Talks with Pfizer Inc. (PFE)

Alnylam Pharmaceuticals (ALNY) and Cubist Pharmaceuticals, Inc. (CBST) Form Strategic Collaboration to Develop and Commercialize RNAi Therapeutics Targeting Respiratory Syncytial Virus (RSV) Infection; Alnylam to Get $20 Million Upfront

BioMarin Pharmaceutical Inc. (BMRN) and La Jolla Pharmaceutical Company (LJPC) Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent; BioMarin May Spend $289 Million for La Jolla's Drug

Endo Pharmaceuticals (ENDP) To Buy Indevus Pharmaceuticals, Inc. (IDEV) in $637 Million Deal

Wyeth Pharmaceuticals (Pennsylvania) (WYE) and Santaris Pharma A/S Announce Strategic Alliance to Develop RNA-based Medicines; Santaris May Receive Payments of up to $83 Million

More Golden Handshakes News

Top Jobs
• Biotech Bay (Palo Alto, California)

CV Therapeutics, Inc.
Vice President, Medical Affairs
The Vice President of Medical Affairs will be responsible for providing leadership to key functional areas within Medical Affairs (Sr. Medical Director and Medical Director(s) and members of the Professional Services team - Medical Information, Medical Science Liaisons).

• Biotech Beach (San Diego, California)

Illumina, Inc.
VP, Array Biochemistry
This position directs the activities of a scientific group in the research and/or development of an organization's products, projects and programs. The position will be responsible for the development of platforms for Genotyping, Gene Expression, and/or Sequencing Systems.

• Bio NC (Raleigh, North Carolina)

PRA International
Vice President, Engagement Partner
Accountable for assigned portfolio of clients from both an operational and business development perspective. Responsible for sales, revenues, and profitability targets for assigned customers.

• Pharm Country (Princeton, New Jersey)

Covance Inc.
Vice President & General Manager Translational Medicine
The Vice President of Translational Medicine in Drug Development is responsible for leading Covances strategy for the successful translation of non-human research to first in human clinical trials on behalf of our clients. In this role, you will be the key interface to opinion leaders, clinicians, scientists, and researchers who conduct analysis of potential drug targets that address a wide range of diseases.

Get Noticed! Add your resume to the BioSpace Career Center!
See more than 5,000 job postings in the BioSpace Career Center!

Pharm Country Career Fair Pharm Country Career Fair
BioSpace is pleased to present the Pharm Country Career Fair on Monday, February 2, 2009 at the Bridgewater Marriott in Bridgewater, NJ.
Biotech Beach Career Fair Biotech Beach Career Fair
BioSpace is pleased to present the Biotech Beach Career Fair on Monday, February 23, 2009 at the San Diego Marriott La Jolla in La Jolla, CA.
Everyone these days know that money talk is mostly about how to hold onto it. And that thrift is ravaging through the life sciences sector in the form of an unprecedented IPO drought, a lack of secondaries, and slow M&A. Especially hard hit are those companies that rely on the capital budgets of hospitals--most particularly medical device makers. Hospitals get their capital budgets from a variety of sources. Many count on charitable contributions (uh-oh!); some even rely on investment gains (yikes!!). So it's a tough time to be trying to convince a hospital to invest in fancy new gadgets, which has led to soft sales and/or warnings from a broad swath of device companies...everyone from robotic surgery expert Intuitive Surgical to heart catheterization company Hansen Medical to diagnostic and imaging company Hologic. At the J.P. Morgan Healthcare conference, device behemoth Stryker said that over half of hospitals have frozen (or nearly frozen) capital spending altogether. Biotechs can take solace in the fact that pharmacy comes from a different budget, but this is a tough time to be introducing anything that even hints at unnecessary novelty. -KT
Intuitive Surgical, Inc. (ISRG) Q4 Revenue Miss Wall Street Expectations

Biotechnology Value Fund, L.P. To Make Tender Offer For Any And All Outstanding Shares Of Avigen, Inc. (AVGN) At $1.00 Per Share or Roughly $20.5 Million

Amgen (AMGN) (JOBS) Sells $2 Billion of Debt in Two-part Sale

Satori Pharmaceuticals Raises $22M; Names Former Senior Pfizer Executive as CEO

Akesis Pharmaceuticals Discontinues Sole Clinical Development Program and Announces Intent to File for Chapter 7 Bankruptcy

More Money Talk News

Alladex: Drug Development Alladex: Drug Development - From Lab to Market
This new set of rapid-learning tools has been developed to enable scientists and business people to learn the key points of drug development from laboratory to market rapidly, easily and cost effectively. The unique 1-Day Alladex Course (now in its fourth year) follows the development of a drug on film from laboratory to market interspersed with key points slides and discussion.
Haas Business of Healthcare Conference Haas Business of Healthcare Conference provides an interdisciplinary forum where cutting-edge information and innovative approaches to health care are shared. This year's Haas Business of Health Care Conference will be held on February 7, 2009 and will focus on the theme "the impact of integration". The event will feature an exciting lineup of keynotes and panel topics.
In the final days of the Bush Administration, FDA okayed guidelines allowing drug companies to distribute medical journal articles describing off-label use of drugs. This modest form of off-label promotion is a slippery slope, critics argue, that could lead to unsafe prescribing and give companies less incentive to do the rigorous studies necessary for label expansion. That's theoretically possible, I suppose, but I've never seen the wisdom to any policy based on denying people information. In any case, it will be an interesting test of the Obama Administration to see if this policy is allowed to stand. Congressional Democrats have generally been hostile to any formalization of off-label promotion -KT
FDA to Allow "Off-Label" Unapproved Drug Promotion

Senators Predict Drug Reimportation Bill Will Finally Pass Congress in This Session

Eli Lilly and Company (LLY) to Pay $1.42 Billion to Resolve Zyprexa Probes

Alexion Pharmaceuticals Inc. (ALXN) to Pay $25 Million to PDL BioPharma, Inc. (PDLI) in Patent Dispute

Celgene (CELG) Warns That Anticlot Drug Linked to Deaths

Common Oral Osteoporosis Drugs Linked To Serious Jaw Necrosis, The FDA Reports

More Legal Briefs News
Why choose Max Neeman International in India? Why choose Max Neeman International in India?
Max Neeman International's M.D. and Ph.D. trained teams maintain the expertise to assist the pharmaceutical, biotech and device industries, in conducting complex clinical trials -- to 'Top 10' pharmaceutical firms, as well as small to midsize biotechnology and device companies.
2009 BIO Human Resources 2009 BIO Human Resources: Our 2009 conference theme is, HR Leading During Times of Change. We are broadening our focus to include global issues, organization and development challenges, strategic issues and best practices from fellow industry professionals. Request for Proposals due Friday, January 30, 2009.
Let the fibromyalgia wars begin! Forest Labs and Cypress Bioscience have gotten FDA's blessing to launch Savella. It will compete against Pfizer's Lyrica--which I've already seen getting more advertising air time--as well as Lilly's Cymbalta. With fibromyalgia being a disease of uncertain etiology and variable symptoms...and with some doctors doubting it even strictly exists outside the mind...companies are likely to count on ad dollars to embolden patients and drive revenue. Cypress is touting a superior label for Savella, which they say is approved to treat a broader array of symptoms than just the pain targeted by Lyrica and Cymbalta. -KT
Forest Laboratories, Inc. (FRX) and Cypress Bioscience Inc. (CYPB) Announce FDA Approval of Savella(TM) for the Management of Fibromyalgia

US FDA Backs Merck & Co., Inc. (MRK) (JOBS), Schering-Plough Corporation (SGP)'s (JOBS) Vytorin

FDA Advisory Committee Unanimously Recommends OVATION Pharmaceuticals, Inc.'s Sabril(R) (vigabatrin) for the Treatment of Two Catastrophic Epilepsies

CSL Behring Receives FDA Approval of RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency

Pfizer Inc. (PFE)'s (JOBS) Bone-Drug Fablyn Fails to Win U.S. Approval

More Rockville Files News
Karl Thiel is an analyst for The Motley Fool, a columnist for BioWorld Today, and a contributor to Nature Biotechnology. He lives in Portland, Oregon.

You may contact Karl Thiel at

East Coast Office:
    BioSpace, Inc.
    Ramshorn Executive Centre
    2399 Highway 34, Building A-5
    Manasquan, New Jersey 08736-1528 U.S.A.
    Phone: 732-528-3688
    Fax: 732-528-3668
West Coast Office:
    BioSpace, Inc.
    90 New Montgomery Street, Suite 414
    San Francisco, California 94105 U.S.A.
    Phone: 877-277-7585
    Fax: 415-576-9217 - Life. Science. Community.

If someone forwarded this news to you and you'd like to receive your own complimentary monthly copy, simply join the BioSpace BioPharm Executive here.

Safely unsubscribe from e-mail at any time by managing your account here.
BioSpace in an onTargetjobs company